CELLEGY RENEGOTIATES RECTOGESIC(R) EU LICENSE AND DISTRIBUTION AGREEMENT WITH PROSTRAKAN GROUP PLC

Cellegy Pharmaceuticals, Inc. (Nasdaq: CLGY -- News) announced today that it has renegotiated the EU License and Distribution Agreement for its product, Rectogesic®, with its licensee, ProStrakan Group plc. Rectogesic is a 0.4% topical nitroglycerin ointment indicated for the relief of pain associated with chronic anal fissures. In September 2004, the product was approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for sale in the UK.

Yahoo News (http://biz.yahoo.com/prnews/051110/sfth014.html?.v=28)